CA2959280C - Vaccine - Google Patents
Vaccine Download PDFInfo
- Publication number
- CA2959280C CA2959280C CA2959280A CA2959280A CA2959280C CA 2959280 C CA2959280 C CA 2959280C CA 2959280 A CA2959280 A CA 2959280A CA 2959280 A CA2959280 A CA 2959280A CA 2959280 C CA2959280 C CA 2959280C
- Authority
- CA
- Canada
- Prior art keywords
- denv
- ediii
- vaccine
- hbsag
- dengue virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims description 51
- 241000725619 Dengue virus Species 0.000 claims abstract description 44
- 229920001184 polypeptide Polymers 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 31
- 208000025729 dengue disease Diseases 0.000 claims description 55
- 206010012310 Dengue fever Diseases 0.000 claims description 52
- 150000007523 nucleic acids Chemical class 0.000 claims description 32
- 230000003472 neutralizing effect Effects 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 239000002105 nanoparticle Substances 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 230000028993 immune response Effects 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims 5
- 208000001490 Dengue Diseases 0.000 description 46
- 102000004169 proteins and genes Human genes 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 229940031351 tetravalent vaccine Drugs 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 229940031626 subunit vaccine Drugs 0.000 description 14
- 241000710829 Dengue virus group Species 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 241000235058 Komagataella pastoris Species 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000002649 immunization Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229940125575 vaccine candidate Drugs 0.000 description 8
- 230000004927 fusion Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 239000002028 Biomass Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- 241000710815 Dengue virus 2 Species 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- 208000002109 Argyria Diseases 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 102100021696 Syncytin-1 Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 229940124590 live attenuated vaccine Drugs 0.000 description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000013520 translational research Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000004231 Riboflavin-5-Sodium Phosphate Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Cartons (AREA)
- Packaging Of Annular Or Rod-Shaped Articles, Wearing Apparel, Cassettes, Or The Like (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2478DE2014 | 2014-09-01 | ||
| IN2478/DEL/2014 | 2014-09-01 | ||
| PCT/IB2015/056352 WO2016034974A1 (en) | 2014-09-01 | 2015-08-21 | Vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2959280A1 CA2959280A1 (en) | 2016-03-10 |
| CA2959280C true CA2959280C (en) | 2023-09-26 |
Family
ID=55439184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2959280A Active CA2959280C (en) | 2014-09-01 | 2015-08-21 | Vaccine |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10189877B2 (enExample) |
| EP (2) | EP3188755B1 (enExample) |
| JP (3) | JP6983653B2 (enExample) |
| CN (1) | CN107074968B (enExample) |
| BR (1) | BR112017004008A2 (enExample) |
| CA (1) | CA2959280C (enExample) |
| CY (1) | CY1123664T1 (enExample) |
| ES (1) | ES2821480T3 (enExample) |
| HR (1) | HRP20201523T1 (enExample) |
| HU (1) | HUE053284T2 (enExample) |
| LT (1) | LT3188755T (enExample) |
| MX (2) | MX385222B (enExample) |
| MY (1) | MY201688A (enExample) |
| PL (1) | PL3188755T3 (enExample) |
| PT (1) | PT3188755T (enExample) |
| RS (1) | RS61000B1 (enExample) |
| SI (1) | SI3188755T1 (enExample) |
| SM (1) | SMT202000589T1 (enExample) |
| WO (1) | WO2016034974A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000589T1 (it) * | 2014-09-01 | 2020-11-10 | Int Centre For Genetic Engineering And Biotechnology | Vaccino |
| US11793873B2 (en) | 2017-05-10 | 2023-10-24 | University Of Massachusetts | Bivalent dengue/hepatitis B vaccines |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766205A (en) * | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
| AU2927892A (en) | 1991-11-16 | 1993-06-15 | Smithkline Beecham Biologicals (Sa) | Hybrid protein between cs from plasmodium and hbsag |
| FR2741077B1 (fr) * | 1995-11-14 | 1998-01-23 | Pasteur Institut | Vaccin polyvalent anti-dengue |
| WO2007034507A2 (en) * | 2005-09-20 | 2007-03-29 | International Centre For Genetic Engineering And Biotechnology | Tetravalent dengue specific domain iii based chimeric recombinant protein |
| WO2008152652A2 (en) * | 2007-06-12 | 2008-12-18 | International Centre For Genetic Engineering And Biotechnology | A dengue envelope domain iii-based tetravalent protein vaccine |
| WO2010043977A2 (en) * | 2008-10-13 | 2010-04-22 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| CN101962411B (zh) * | 2009-07-24 | 2012-09-05 | 中国疾病预防控制中心病毒病预防控制所 | 登革病毒血清学早期诊断试剂 |
| MX2012012681A (es) * | 2010-05-21 | 2012-12-17 | Univ Pittsburgh | Secuencias del virus de dengue universales y metodos de uso. |
| CN103193870B (zh) * | 2013-04-22 | 2014-10-22 | 中国人民解放军第三军医大学 | 一种登革病毒简并疫苗及其应用 |
| SMT202000589T1 (it) * | 2014-09-01 | 2020-11-10 | Int Centre For Genetic Engineering And Biotechnology | Vaccino |
-
2015
- 2015-08-21 SM SM20200589T patent/SMT202000589T1/it unknown
- 2015-08-21 PL PL15775490T patent/PL3188755T3/pl unknown
- 2015-08-21 MY MYPI2017700715A patent/MY201688A/en unknown
- 2015-08-21 MX MX2017002621A patent/MX385222B/es unknown
- 2015-08-21 CN CN201580046960.4A patent/CN107074968B/zh active Active
- 2015-08-21 BR BR112017004008-5A patent/BR112017004008A2/pt active Search and Examination
- 2015-08-21 JP JP2017511582A patent/JP6983653B2/ja active Active
- 2015-08-21 WO PCT/IB2015/056352 patent/WO2016034974A1/en not_active Ceased
- 2015-08-21 ES ES15775490T patent/ES2821480T3/es active Active
- 2015-08-21 SI SI201531356T patent/SI3188755T1/sl unknown
- 2015-08-21 EP EP15775490.4A patent/EP3188755B1/en active Active
- 2015-08-21 US US15/506,379 patent/US10189877B2/en active Active
- 2015-08-21 PT PT157754904T patent/PT3188755T/pt unknown
- 2015-08-21 HR HRP20201523TT patent/HRP20201523T1/hr unknown
- 2015-08-21 CA CA2959280A patent/CA2959280C/en active Active
- 2015-08-21 HU HUE15775490A patent/HUE053284T2/hu unknown
- 2015-08-21 EP EP19215426.8A patent/EP3685852A1/en active Pending
- 2015-08-21 RS RS20201131A patent/RS61000B1/sr unknown
- 2015-08-21 LT LTEP15775490.4T patent/LT3188755T/lt unknown
-
2017
- 2017-02-27 MX MX2021006543A patent/MX2021006543A/es unknown
-
2018
- 2018-12-06 US US16/211,564 patent/US10815280B2/en active Active
-
2020
- 2020-06-03 JP JP2020096790A patent/JP6985458B2/ja active Active
- 2020-09-22 CY CY20201100890T patent/CY1123664T1/el unknown
- 2020-10-22 US US17/077,206 patent/US11945842B2/en active Active
-
2021
- 2021-11-25 JP JP2021191104A patent/JP7333373B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tripathi et al. | Recent developments in recombinant protein–based dengue vaccines | |
| Poggianella et al. | Dengue E protein domain III-based DNA immunisation induces strong antibody responses to all four viral serotypes | |
| US20210355167A1 (en) | Neutralising antibody against dengue for use in a method of prevention and/or treatment of zika infection | |
| AU2015279375B2 (en) | A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection | |
| Kim et al. | Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection | |
| De Lorenzo et al. | Zika virus-like particles bearing a covalent dimer of envelope protein protect mice from lethal challenge | |
| JP7333373B2 (ja) | ワクチン | |
| WO2015019253A2 (en) | Anti-dengue virus genetic vaccine based on the envelope protein ectodomains | |
| HK40032428A (en) | Vaccine | |
| JP2011502521A (ja) | Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法 | |
| US10772949B2 (en) | Dengue virus glycoprotein E DIII variants and uses thereof | |
| JP7221995B2 (ja) | フラビウイルスの成熟ウイルス様粒子 | |
| Chen et al. | Selection of immunodominant fragments from envelope gene for vaccine against Japanese encephalitis virus in DNA priming–protein boosting protocols | |
| WO2025146159A1 (zh) | 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用 | |
| WO2017031280A1 (en) | Fusion proteins that include dengue antigens and methods of use | |
| Trindade et al. | Retention of a recombinant GFP protein expressed by the yellow fever 17D virus in the E/NS1 intergenic region in the endoplasmic reticulum | |
| EP2408464A2 (en) | Hcv-derived polypeptides and uses thereof | |
| BR112017001340B1 (pt) | Epítopo de dímero e, composição, composição farmacêutica, kit, método para a síntese do ede e para produzir um anticorpo ou porção de ligação ao antígeno do mesmo, método in vitro para monitorar a progressão ou regressão de uma infecção por vírus da dengue ou prever a evolução no tempo da mesma, para diagnosticar uma infecção por vírus da dengue e para monitorar o sucesso de um protocolo de vacinação contra uma infecção de vírus da dengue e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200818 |
|
| EEER | Examination request |
Effective date: 20200818 |
|
| EEER | Examination request |
Effective date: 20200818 |
|
| EEER | Examination request |
Effective date: 20200818 |
|
| EEER | Examination request |
Effective date: 20200818 |
|
| EEER | Examination request |
Effective date: 20200818 |
|
| EEER | Examination request |
Effective date: 20200818 |
|
| EEER | Examination request |
Effective date: 20200818 |